Quick Answer
Resveratrol Inflammation Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia.
Key Takeaways
- 01The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia. [Gazda P (2026)]
- 02The analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%). [Gazda P (2026)]
- 03Curcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels. [Gazda P (2026)]
- 04Metabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide. [Gazda P (2026)]
The current Migaku evidence database contains 2 reusable source documents for Resveratrol Inflammation Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia. [Gazda P (2026); evidence level 1]
- The analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%). [Gazda P (2026); evidence level 1]
- Curcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels. [Gazda P (2026); evidence level 1]
- Metabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide. [Gazda P (2026); evidence level 1]
- As a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified. [Russo C (2026); evidence level 1]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources